Overview Dividends

(ZIVO) Zivo Bioscience - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98978N2009

Algae, Bioactive Ingredients, Animal Feed, Human Supplements, Medical Food

ZIVO EPS (Earnings per Share)

EPS (Earnings per Share) of ZIVO over the last years for every Quarter: "2020-03": -3.0396581400908, "2020-06": -1.3869428265779, "2020-09": -4.1340198276879, "2020-12": -2.2144823956018, "2021-03": -2.5602607592016, "2021-06": -1.7060898502496, "2021-09": -1.788166019597, "2021-12": -0.33592354321263, "2022-03": -1.2920058602459, "2022-06": -1.3197267341869, "2022-09": -1.2767303649914, "2022-12": -1.6821421746608, "2023-03": -1.2568583986241, "2023-06": -1.3189196764125, "2023-09": -1.0512829080016, "2023-12": -1.0994567659427, "2024-03": -0.46519157297238, "2024-06": -2.7810534846029, "2024-09": -0.6651996833216, "2024-12": -0.46955928923293, "2025-03": -1.1229535212394, "2025-06": -0.43049578751214,
EPS Growth (3Y CAGR): 32.65%
EPS Trend (3Y Correlation): 47.1%

ZIVO Revenue

Revenue of ZIVO over the last years for every Quarter: 2020-03: 0.02, 2020-06: 0, 2020-09: 0, 2020-12: 19.98, 2021-03: 19.98, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0.00405, 2023-09: 0.0118, 2023-12: 0.0118, 2024-03: 0.03572, 2024-06: 0, 2024-09: 0.0315, 2024-12: 0.09, 2025-03: 0, 2025-06: 0.0534,
Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): 59.9%

Description: ZIVO Zivo Bioscience

from quarterly Tax Provision

ZIVO Stock Overview

Market Cap in USD 65m
Sub-Industry Personal Care Products
IPO / Inception 2012-09-24

ZIVO Stock Ratings

Growth Rating 40.9%
Fundamental 45.9%
Dividend Rating -
Return 12m vs S&P 500 27.9%
Analyst Rating 3.0 of 5

ZIVO Dividends

Currently no dividends paid

ZIVO Growth Ratios

Growth Correlation 3m 21%
Growth Correlation 12m -28.3%
Growth Correlation 5y 6.2%
CAGR 5y 97.29%
CAGR/Max DD 5y 0.99
Sharpe Ratio 12m -0.03
Alpha 81.85
Beta 0.961
Volatility 87.68%
Current Volume 0k
Average Volume 20d 0.9k
Stop Loss 16.1 (-5.3%)
Signal -0.56

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-9.72m TTM) > 0 and > 6% of Revenue (6% = 10.5k TTM)
FCFTA -6.13 (>2.0%) and ΔFCFTA 394.3pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -1458 % (prev -4006 %; Δ 2548 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -5.54 (>3.0%) and CFO -3.90m > Net Income -9.72m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 0.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (3.81m) change vs 12m ago 28.65% (target <= -2.0% for YES)
Gross Margin 31.09% (prev 35.00%; Δ -3.91pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 27.35% (prev 10.31%; Δ 17.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -163.8 (EBITDA TTM -3.86m / Interest Expense TTM 23.3k) >= 6 (WARN >= 3)

ValueRay F-Score (Strict, 0-100) 45.88

1. Piotroski 0.0pt = -5.0
2. FCF Yield -6.59% = -3.29
3. FCF Margin data missing
4. Debt/Equity data missing
5. Debt/Ebitda -0.14 = -2.50
7. RoE data missing
8. Rev. Trend 59.94% = 3.00
9. Rev. CAGR 0.0% = 0.0
10. EPS Trend 47.14% = 1.18
11. EPS CAGR 32.65% = 2.50

What is the price of ZIVO shares?

As of August 31, 2025, the stock is trading at USD 17.01 with a total of 0 shares traded.
Over the past week, the price has changed by -5.50%, over one month by +58.97%, over three months by +9.25% and over the past year by +50.53%.

Is Zivo Bioscience a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Zivo Bioscience (NASDAQ:ZIVO) is currently (August 2025) a stock to sell. It has a ValueRay Fundamental Rating of 45.88 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZIVO is around 15.42 USD . This means that ZIVO is currently overvalued and has a potential downside of -9.35%.

Is ZIVO a buy, sell or hold?

Zivo Bioscience has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold ZIVO.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ZIVO price?

Issuer Target Up/Down from current
Wallstreet Target Price 12 -29.5%
Analysts Target Price 12 -29.5%
ValueRay Target Price 17.3 1.9%

Last update: 2025-08-30 05:04

ZIVO Fundamental Data Overview

Market Cap USD = 64.9m (64.9m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 9823 USD (Cash And Short Term Investments, last quarter)
P/S = 371.2246
P/B = 21.1296
Beta = -0.037
Revenue TTM = 174.9k USD
EBIT TTM = -3.81m USD
EBITDA TTM = -3.86m USD
Long Term Debt = 47.0k USD (from longTermDebt, last quarter)
Short Term Debt = 494.6k USD (from shortTermDebt, last quarter)
Debt = 541.6k USD (Calculated: Short Term 494.6k + Long Term 47.0k)
Net Debt = 769.3k USD (from netDebt column, last quarter)
Enterprise Value = 65.5m USD (64.9m + Debt 541.6k - CCE 9823 )
Interest Coverage Ratio = -163.8 (Ebit TTM -3.81m / Interest Expense TTM 23.3k)
FCF Yield = -6.59% (FCF TTM -4.31m / Enterprise Value 65.5m)
FCF Margin = -2466 % (FCF TTM -4.31m / Revenue TTM 174.9k)
Net Margin = -5558 % (Net Income TTM -9.72m / Revenue TTM 174.9k)
Gross Margin = 31.09% ((Revenue TTM 174.9k - Cost of Revenue TTM 120.5k) / Revenue TTM)
Tobins Q-Ratio = -0.46 (set to none) (Enterprise Value 65.5m / Book Value Of Equity -142.8m)
Interest Expense / Debt = 1.36% (Interest Expense 7360 / Debt 541.6k)
Taxrate = 21.0% (US default)
NOPAT = -3.81m (EBIT -3.81m, no tax applied on loss)
Current Ratio = 0.14 (Total Current Assets 409.9k / Total Current Liabilities 2.96m)
Debt / EBITDA = -0.14 (Net Debt 769.3k / EBITDA -3.86m)
Debt / FCF = -0.13 (Debt 541.6k / FCF TTM -4.31m)
Total Stockholder Equity = -1.69m (last 4 quarters mean)
RoA = -1382 % (set to none)
RoE = unknown (Net Income TTM -9.72m / Total Stockholder Equity -1.69m)
RoCE = unknown (Ebit -3.81m / (Equity -1.69m + L.T.Debt 47.0k))
RoIC = unknown (NOPAT -3.81m, Invested Capital -1.25m, Ebit -3.81m)
WACC = 9.49% (E(64.9m)/V(65.5m) * Re(9.56%)) + (D(541.6k)/V(65.5m) * Rd(1.36%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 0.0 | Cagr: -20.25%
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -4.31m)
Revenue Correlation: 59.94 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -88.00
EPS Correlation: 47.14 | EPS CAGR: 32.65%
EPS Growth-of-Growth: 16.51

Additional Sources for ZIVO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle